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 Allergy and asthma are the most common diseases associated with cockroach infestation 
of houses in the United States and other parts of the world. Allergy to cockroach has been 
recognized as a significant health problem world-wide, and is often coupled with urban 
development and inner-city environments. In the United States the prevalence of cockroach 
allergy ranges from 17% to 41% in both adults and children, and allergic diseases constitute the 
most common chronic diseases of childhood and represent approximately 25% of children's sick 
visits to pediatricians.  
 The principal domestic cockroach species are Blattella germanica (German cockroach) 
and Periplaneta americana (American cockroach). The German cockroach is the most common 
species associated with allergies in the US and Europe, and the American cockroach is found 
more commonly in South America and some Asian countries. Both species produce several 
potent allergens, including Bla g 2, an inactive aspartic proteinase; Bla g 4, a calycin, Bla g 5, a 
glutathione-S-transferase, and the group 1 cross-reactive allergens Bla g 1 and Per a 1. Of these, 
Bla g 2 appears to be an especially potent allergen, which elicits IgE responses at exposure levels 
that are hundreds fold lower than other cockroach allergens.  
 Currently subcutaneous injection immunotherapy is the only potentially curative 
treatment available for allergy, but has clear disadvantages and is not acceptable to many 
children. Also treatment by injection can carry great risks such as anaphylactic shock, especially 
for food allergies. Our research group is actively involved in the development of sublingual 
immunotherapy (SLIT). In this work, a formulation of orally dissolving thin film has been 
developed and characterized. The film allows for higher and more effective dosing, and its 
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mucoadhesiveness prolongs the effect of the allergen and leads to enhanced immunotherapy for 
asthma.  
 It is found in this work that the formulation developed for the treatment of German 
cockroach allergy incorporates a significant amount of the Bla g 2 allergen. Its potency and 
stability have been characterized by enzyme-linked immunosorbent assay (ELISA), and other 
pharmacological properties are evaluated by spectroscopic methods. This SLIT methodology has 
the potential to change the face of immunotherapy for both food and inhalant allergies in adults 
and children. This essay will provide an overview of the development and characterization of Bla 
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 Inner city residents suffer disproportionate asthma incidences compared to their suburban 
counterparts in the United States. Although many factors may be responsible for these 
disparities, there is a growing body of evidence to show that indoor environments play a key role 
in asthma control and other asthma related health issues in inner-city populations. The term 
"inner-city" refers to impoverished urban neighborhoods with dilapidated and poorly kept 
housing, where there is an increased chance for pest infestations and "asthmagenic" exposures. 
Among the major categories of indoor allergens are endotoxins, pollutants, and biologics 
including those from dust mites, pets, rodents and cockroaches2. Studies have found that more 
than half of asthma cases in the United States is caused by allergic sensitization3, and in one 
inner-city study of children with poorly controlled asthma, a staggering 94% of children showed 
evidence of allergic sensitization to some form of indoor allergen2. While majority of the 
previously listed indoor allergens can be found in inner-city homes across the country, there is a 
geographical pattern to the distribution of allergens4,5,6. For example, Dust mite is the 
predominant indoor allergen in southern US while cockroach is more often found in northeastern 
regions of the country. Therefore it is important to understand the geographical relevance of the 
allergens and provide tailored testing as well as treatment to patients.  
 In this current study we chose the German cockroach as the target allergen of our 
sublingual immunotherapy (SLIT) development. Many species of cockroaches generate a wide 
group of allergens with diverse structural variations and biological functions. They are released 
into the environment through the digestive tract of the insect or excretion with feces. The 
allergenic particulates are large and settles onto surfaces easily. Usually disturbance of the dust is 
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required for sensitization, however in the case of the cockroach allergen, miniscule amounts of 
unsettled dustis sufficient to induce allergic sensitization9. 
 Multiple allergens from various species of cockroaches have been characterized, and 
eight groups of cockroach allergens have been added to the World Health Organization (WHO) 
list of Allergen Nomenclature, including the German cockroach B. germanica allergens Bla g 1, 
Bla g 2, Bla g 4, Bla g 5, Bla g 6, Bla g 7 and Bla g 8, and the American cockroach P. americana 
allergens Per a 1, Per a 2, Per a 3, Per a 6 and Per a 74. (Table 1) Contrary to its name, the 
American cockroach is predominantly found in South America and some Asian countries, 
whereas the German cockroach is mainly found in the United States9. For this reason 
currentinner-city asthma studies have primarily focused on the German cockroach (Bla g) 
allergens, and more specifically, Bla g 2. Bla g 2 is a very potent allergen that elicits more than 
60% of IgE antibody response at exposure levels 10-100 fold lower than that of other common 
indoor allergens3. The Bla g 2 allergen was successfully cloned in 1995 and in 2005 Gustchinaet 
al10 solved its crystal structure.  
 Bla g 2 is a 36 kDa glycoprotein that shares homology with the aspartic protease family10 
(Figure 1). Aspartic proteases are enzymes that use aspartate to catalyze target substrates. These 
enzymes share two conserved aspartate residues in the active site which is commonly inhibited 
by pepstatin. The crystal structure of Bla g 2 shows a bilobal shape that is typical of aspartic 
proteases, and a cleft between them that contains the catalytic site. Sequence similarity between 
Bla g 2 and other aspartic proteases is close. For example, there is a 52% similarity between Bla 
g 2 to pepsin, chymosin and renin, and 49% between it and proteinase A.10 (Figure 2) However, 
Bla g 2 differs from this family of protein in several ways. First, Bla g 2 has a metal binding site 
that is occupied by a tightly bound zinc cation.10 (Figure 3) Three out of the four residues that 
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form this binding site are unique to the sequence of Bla g 2 and have not been found in other 
related cockroach allergens.10 Second, five disulfide bridges are found in the structure of Bla g 2, 
and only two of them are conserved within the pepsin family while the remaining three do not 
have structural analogs in other identified aspartic proteases. Similarly, a disulfide bridge found 
in other aspartic proteases is absent in the Bla g 2 structure. Substitutions of the amino acid 
glycine by serine or threonine, as well as insertions in the active site renders this Bla g 2 to an 
inactive aspartic protease.10 
 The stability of the Bla g 2 allergen can be attributed to an increased number of disulfide 
bridges and the incorporation of the zinc cation. In allergic sensitization, the stability of the 
tertiary structure of the allergen is crucial to IgE recognition. Disruption to the native structure 
leads to reduced sensitivity. Bla g 2 has five disulfide bridges instead of the two or three usually 
found in other aspartic proteases. The number of disulfide bridges in a protein molecule often 
correlates with its stability, and in addition the zinc cation strengthens the two neighboring 
secondary structures of the protein. The increased structural stability can influence the 
persistence of the allergen in the environment, and chronic exposure to such a stable allergen can 
explain why even at low doses (< 1ug/g dust)9 it is still able to elicit an allergic reaction.  
 The National Cooperative Inner City Asthma Studies declares that 37% of children with 
asthma in the United States have been exposed and show sensitization to cockroach allergens9. 
The highest values of cockroach exposure of up to 81% are found in Bronx, New York and 
Dallas, Texas9. At least 50% of inner-city homes have been shown to have clinically relevant 
levels of cockroach allergen4,7, and 30% of suburban homes show detectable levels of the 
allergen5,8. Numerous studies over decades have demonstrated that the combination of cockroach 
allergy and cockroach exposure is one of the most important factors leading to high morbidity in 
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inner-city children with asthma11. The National Institute of Allergy and Infectious Diseases 
sponsors the Inner-City Asthma Consortium (ICAC), whose main goal is to develop immune-
based treatments for cockroach allergy that focuses on the root of the disease instead of its 
management. There are significant risks associated with allergy treatments especially in small 
children, one of which is the potential for anaphylactic shock during immunotherapy11. The most 
common immunotherapy in the United States is subcutaneous injectable immunotherapy 
(SCIT)12. The major drawbacks to this therapy are acceptability and safety. SCIT requires 
regular injections over a prolonged period of time, and this leads to only a small fraction of 
children who could potentially benefit from this therapy to be treated with it. Also, systemic 
allergic reactions are relatively common with SCIT treatment, especially for respiratory allergies 
such as cockroach, occurring in one out of nine test subjects.13   
 Recently the use of liquid extracts were tested. These extracts are the most common form 
of sublingual immunotherapy in the US in studies of both food and respiratory allergies, but they 
cannot be easily concentrated to the doses likely to be effective in immunotherapy. A previous 
dose at 3.3μg was evaluated but after 6 months of treatment there was no change in allergen 
specific IgG 4 [unpublished data], an antibody that is postulated to be important for the 
mechanism of immunotherapy.  
 A dissolving film could be a viable alternative to both SCIT treatment and also treatment 
by liquid allergen extracts. Film drug delivery is a method of delivering drugs using a thin film 
that dissolves when in contact with liquid (eg. saliva), and delivers the active compound to the 
systemic circulation.  A thin film formulation allows for safer and more patient-compliant 
therapy, more effectively stabilizes the enzymatic activity of the allergenic protein, and also 
delivers a much higher dose. 
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 Commonly referred to as sublingual immunotherapy (SLIT), thin film formulations offer 
the potential to improve the onset of action, lower the required dosage, and enhance the safety 
and efficacy of the treatment. Most oral dosage forms enter the blood stream through the 
gastrointestinal (GI) tract, which subjects the drug first to degradation in the acidic environment 
of the stomach, then bile, digestive enzymes, and all other first pass effects. A higher initial 
dosage is therefore required to achieve the desired end result, and due to the traveling time in the 
GI tract, onset of action can be significantly delayed. Sublingual dosing avoids these issues to 
yield quicker onsets and lower doses. Also, the film's ability to dissolve without water, and 
elimination of the needle naturally makes it an attractive drug delivery regimen for pediatric 
patients where compliance can be difficult.13 
 Cockroach allergy is a key contributor to asthma morbidity in inner-city children. Pilot 
studies lead by the Johns Hopkins School of Medicine document the immune responses of inner-
city residents to cockroach allergen and provide directions for the development of 
immunotherapy which ultimately lead to the research that forms the topic of this essay. We have 
developed a SLIT film for the treatment against Bla g 2 allergies. The films are formulated with 
25ug of Bla g 2 allergen per single dose, nearly 10 fold higher compared to using only liquid 
extracts, and without the safety drawbacks of SCIT treatments. We characterized the film 
formulation based on its appearance and physical properties, confirmed allergen content using 
enzyme-linked immunosorbent assay (ELISA), and tested in vitro dissolution and disintegration 
via spectroscopic methods. Our results show that the thin film formulation is uniform in allergen 
content, with allergen release profiles that meet the preset requirements, and also possess 




Orally Dissolving Strips: 
  
 The oral route is a convenient method of drug administration because of its ease of 
dosing, cost effectiveness as well as high levels of patient compliance. It can become 
problematic however for pediatric and geriatric patients who may have fear of choking or 
difficulty swallowing. Recently fast dissolving drug delivery systems have gained popularity for 
their increased convenience, rapid dissolution and disintegration, and self-administration even 
without water. Various mucoadhesive dosage forms have been investigated, including tablets, 
gels, ointments, patches and as is seen in this study, quick-dissolving films. An ideal fast 
dissolving delivery system should possess high formulation stability, transportability, ease of 
handling and administration, requires no special packaging or storage conditions, have a pleasant 
taste, and more importantly have a tunable dissolution time. Materials chosen for the formulation 
of thin films include film-forming water-soluble polymers, plasticizers, the active ingredient, 
sweetening/flavoring agents, coloring agents, stabilizing or thickening agents. The excipients 
used should be approved for use in oral pharmaceutical dosage forms by the US Food and Drug 
Administration (FDA).14 
 The first kind of oral strip was developed by Pfizer and marketed under the name 
Listerine® pocket packs™. Chloraseptic® was the first therapeutic oral thin film which 
contained 7-benzocaine for the treatment of sore throat. The films are usually formulated to be 
1–20cm2 in size and drug loading of up to 30 mg.14 The polymer of choice, along with 
plasticizers, stabilizing or thickening agents heavily influence the mechanical properties of the 
film as well as its long term shelf life. A variety of polymers and related excipients are available 
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for the formulation of orally dissolving strips, also available is a wide array of manufacturing 
techniques.  
 A variety of polymers are available for the formulation of fast dissolving oral films. The 
properties of the selected polymers are crucial to the successful development of the formulation. 
The principle criteria for the polymer excipients include:14 
 - they should be nontoxic and nonirritant with none or minimal impurities; 
 - they do not affect drug release profile; 
 - they are devoid of offensive odor or taste; 
 - theyexhibit good wetting and mucoadhesive property; 
- they have sufficient peel, shear and tensile strength; 
 - they are cost effective; and  
 - they have desirable shelf life. 
  
 Table 2 provides a list of the currently available natural and synthetic polymers used in 
formulating orally dissolving strips. Tables 3 and Table 4 represent the quality parameters of 
these polymers, respectively. Conventional approaches to formulating fast-dissolving films 
include the following14, and a brief description for each is given below.  
 - Solvent casting 
 - Hot melt extrusion 
 - Semisolid casting 
 - Solid dispersion extrusion 







 In this method, water-soluble polymers are dissolved in aqueous media at elevated 
temperatures (60-90°C) under agitation. The polymer solution is mixed with the appropriate 
concentrations of other excipients such as coloring and flavoring agents and finally the active 
ingredient is incorporated. Air bubbles can be removed by vacuum or brief sonication. The 
resulting solution is poured into the mold and allowed to dry. Afterwards, the dried sheets are cut 
into the desired size.14 
 
Hot melt extrusion 
 
 In the hot melt extrusion method, the initial formulation is formed with the help of 
carriers to obtain a solid mass and dried. The dried intermediate product is introduced into the 
extruder and re-melted at the desired temperature. The extrudate is pressed into a film. The main 
advantage with this method is better content uniformity, since in such a melt sedimentation of 




 Semi-solid casting is the preferred method when one of the excipients is an acid insoluble 
polymer, for example, cellulose acetate phthalate or cellulose acetate butyrate. To begin, the 
water-soluble polymers are dissolved in aqueous media and the solution is added to the acid 
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insoluble polymer solution that is prepared separately. The ratio of the acid insoluble polymer to 
the film-forming polymer should be no greater than 1:4. After mixing, a plasticizer is added to 
form a gel and to enhance the final film's physical properties. The gel is casted into the film and 
processed by standard methods.14 
 
Solid dispersion extrusion 
 
 This method involves the solid dispersion of the drug in a melted polymer solution. The 
drug is first dissolved in a liquid solvent and then added to the melt of the selected polymer. 
They are mixed thoroughly without removing the liquid solvent to obtain the solid dispersion. 




In this method, both the drug solution and film-forming polymer are mixed together and 
the resulting solution or suspension is subjected to a processing roller. The rolled out sheets are 
dried and cut into the desired shapes and sized.14 
 
 Clearly fast dissolving thin films can be an advantageous approach to oral drug delivery. 
It promises patient compliance especially in children and for immunotherapy purposes, it is also 
considered a much safer route of administration compared to the more widely used subcutaneous 
injection method. The films are easy to formulate, process and scale up. A successful sublingual 
thin film formulation could potentially change the future of immunotherapy.  
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 Defatted ground cockroach source powder was purchased from Greer, USA. Methocel E 
15 LV Premium was obtained from The DOW Chemical Company, Midland, Michigan. 
Glycerin NF grade was obtained from Spectrum Chemical MFG Corp., and distilled and 
deionized water used in the formulation and all experimental analyses was obtained through a 
Milli Q water purification system (Millipore Corp.) All of the above materials were of analytical 
grade.  
 The Bla g 2 ELISA kit was purchased from Indoor Biotechnologies. The protocol was 
modified to be used with anti-rabbit HRP (horseraddish peroxidase), which was obtained from 
Thermo Scientific. 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) or ABTS was 
purchased in its powder form from Invitrogen.  
 
Preparation of Blatellagermanica crude extract 
 
 Powdered German cockroach source material was kept frozen at –20°C until used. The 
allergen solution was prepared by suspending the powdered source material at 20% w/v in 
deionized water and incubating the suspension at 4°C overnight. Afterwards the suspension was 
taken out and centrifuged at 3000X g at 4°C for 15 minutes, and collecting the supernatant. The 




Preparation of SLIT thin films  
 
 A solvent casting method was used to prepare the thin filmstrips used to deliver the 
cockroach allergen extract. The optimized composition of the film is tabulated in Table 5. 
Cockroach protein extract, Methocel E 15, glycerin, water, and chocolate flavoring agent were 
mixed in a suitable vial followed by brief, pulsed ultrasonic defoaming to remove the air bubbles 
in the solution. The solution was cast onto a flat Teflon cast that has dimensions of 2.5cm  5cm, 
which was custom-made. The films were dried overnight in a 40°C oven to evaporate the excess 
water, and then gently peeled off the cast. The edges of the films were trimmed off, and they 
were cut into 1cm  2cm strips. Bla g 2 content in each strip was assayed using ELISA.  
 
Weight  and Thickness 
 
 The weight and thickness of the 1cm  2 cm film-strips were measured. Weight was 
measured by an analytical balance (Mettler Toledo, Inc), while thickness was measured using a 
calibrated digital Vernier Calipers (Cen-Tech®).The thickness of each strip was evaluated at five 
different locations (four corners and one center) as shown in the schematic diagram below.14 The 
data helps to ascertain the physical uniformity of the films as it is directly related to the accuracy 







 Foldability was assessed by folding each 1cm  2cm film-strip repeatedly at the same 
place as indicated by the dashed line until breakage occurs or visible cracks began to appear. A 
total of three strips were tested. The number of times the strip could be folded without breaking 







 Tensile strength was measured using a Dynamic Mechanical Analysis instrument (DMA 
Q800). The instrument was equipped with one fixed clamp and one movable clamp, which 
extends to induce strain on the specimen. Each film strip was loaded securely into the clamps 
and pulled at a constant rate of 100 μm per minute to a maximum extension of 2000 μm (10% 
elongation). The result was recorded on an engineering stress vs strain curve. The highest point 
of the curve was reported as the ultimate tensile strength, and the slope of the linear portion of 







 To assess the water content of the thin film, they were weighed at the end of the casting 
process, and then put into separate borosilicate scintillation vials and lyophilized for periods of 
12 hours. At the end of each period, the films were extracted and allowed to return to ambient 
conditions in a desiccator before re-weighing. Afterwards they were placed back into 
lyophilization. This process was continued until two consecutive weighings did not differ by 
more than 0.50 mg (1% of total strip weight) per each strip. The difference in initial and end 
weight was recorded as the absolute water content of the strip.  
 
Surface pH test 
 
 The surfaces of the films were wetted slightly with deionized water and its pH measured 
by bringing the electrode into contact with the wetted surface.  
 
In vitro disintegration test   
 
 Disintegration here is referred to as the physical process by which the film dissolves into 
a solution. Disintegration time was measured for three strips according to a method previously 
described by Balaet al.14 Briefly, the film stripwas dipped in 25 mL of water in a suitable 
container. The water was gently agitatedby a 1-inch stir bar at 75 rpm. Disintegration time was 




In vitro dissolution test  
  
 In vitro dissolution time was measured in accordance to the conditions set out in the 
United State Pharmacopeia. 900 mL of fresh deionized water was added to a suitable container 
as the dissolution media. The media temperature was maintained at 37 ± 0.5°C. The medium was 
agitated by a 1-inch Teflon®-coated stir bar rotating at 75 rpm. At time points 10, 15, 20, 25, 30, 
45 and 60 minutes, 1 mL aliquots of samples were extracted and measured on an UV/Vis 
spectrophotometer (Thermo Scientific, NanoDrop, 2000c) at wavelength 300 nm. The resulting 




 The dosage uniformity of the Bla g 2 allergen was quantitated using the ELISA assay for 
ten filmstrips. Each film was fully dissolved in 1 mL of water and then pre-diluted 100 fold 
before they were loaded onto a 96-well microtiter plate for ELISA. The amount of Bla g 2 was 
quantitated based on the logarithmic fit of the ELISA standard curve. The contents of each of the 
strip was to be between 85% and 115% and the relative standard deviation is less than or equal to 
6.0%. The acceptance value (AV) of the sample preparations much be less than 15%, according 
to the United States Pharmacopeia. The AV is calculated according to the following equation:  
 




where, M is the label claim (100%), X the average (%) of the individual samples, k the 







Preparation of Blatella germanica crude extract 
 
 The Bla g 2 concentration in the aqueous extract solution was measured for three separate 
protein extracts and the average amount of Bla g 2 extracted from the crude source material was 
determined to be 155.8 μg/mL ± 23.7 μg/mL. Percent relative standard deviation (% RSD) is 
defined as the absolute value of the coefficient of variation. It is widely used to express the 
precision and repeatability of an assay. The % RSD of this assay was 15.2%. Based on our past 
experiences and the inherent variability in ELISA for allergens, a % RSD of less than equal to 
20% is considered an acceptable level of variation in the assay data.   
 
Preparation of SLIT thin films  
 
 The optimized composition of the thin film incorporated 25 μg per strip of the potent 
German cockroach Bla g 2 allergen in each of the 1 cm  2 cm strip, as determined by ELISA 
assay.  The selected composition demonstrated the most satisfactory physical properties. The 
films dried tack-free, easily peeled from the cast, could be cleanly cut into desired dimensions, 





Weight  and Thickness 
 
 The average weight of the filmstrips were found to be 41.7 mg ± 3.4 mg (Mean ± SD, 
n=10), with % Relative Standard Deviation (RSD) of 8.2%. Typically variance of <10% was 
considered an adequate level of reproducibility. The weight of blank filmstrips averaged 24.8 mg 
± 2.2 mg, with % RSD of 8.9%. As expected, strip weight increased when the more dense 
allergen extract was incorporated.  
 Thickness measurements were taken for ten strips at the five designated locations shown 
previously. The mean thickness was first calculated for each strip then averaged across all ten 
samples. The total mean thickness of the strips was determined to be 78.0 μm ± 21.8μm (Mean ± 
SD, n=10).The filmstrips tended to be thicker near the edges due to the effect of drying. The 
films were casted using molds fabricated locally with limited selection of size, which constrained 
our ability to excise the desired dimensions while avoiding edges. We fully anticipate that when 
this study proceeds to cGMP manufacturing, where much larger molds are employed, these 
variations in thickness would be significantly reduced. We report here also the thickness at the 
center of the strips as 93.0 μm ± 13.4 μm, which strengths our hypothesis that more uniform 
thickness distribution will be achieved once the edge effect is eliminated.  
 The thickness of blank filmstrips were also measured, and averaged to be 64.3 μm ± 9.8 
μm. This result correlates with the strip weight data. As expected, the blank filmstrips are lighter 






 We also determined the foldability of the filmstrips, to confirm that they possess the 
necessary flexibility for each maneuver. Multiple strips with the highest protein extract content 
were tested, as flexibility decreases with increased extract percentage. The average number of 
folds the films can endure before cracks were observed or complete failure was 11.0 ± 1.0  
(Mean ± SD, n = 3).   
 The foldability of three blank filmstrips were also tested. The blank filmstrips were much 
more flexible compared to their active counterparts, and the foldability for each of the three 
tested strips exceeded 100 folds.   
 
Tensile strength 
 Tensile strength, or more properly, ultimate tensile strength (UTS), is an important 
mechanical property for thin films. It measures the maximum stress that the film can withstand 
while being stretched or pulled before failing or breaking. The UTS of the strips with the highest 
protein loading level (40%) was tested to be 15.0 MPa ± 5.3 MPa. Based on the behavior of the 
filmstrips we concluded that they possess sufficient physical integrity to allow easy processing 
and handling during manufacturing, transportation, and storage. A typical stress-strain curve for 
a filmstrip is shown in Figure 5.  




 The filmstrips were determined to contain on average 2.9% ± 0.8% of water (n = 8). 
Water content is an important criteria as it can directly affect the shelf life of the filmstrips. At 
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the time this thesis was being prepared, a cGMP-compliant study is in progress to correlate the 
water content in films and their maximum shelf life.  
 
Surface pH test 
 
 Surface pH was recorded for three filmstrips. The average pH was 6.4 ± 0.3 (mean ± SD), 
RSD was 4.0%. Surface pH provides guidance on the acidity of the filmstrips after processing. 
The pH should be neutral or close to neutral as to not cause irritation to the oral mucosa during 
administration. The obtained pH value conforms to this criterion, as it is comparable to the pH of 
common drinking water which is between 6.5 to 8.5, according to guidelines by the World 
Health Organization.  
 
In vitro disintegration test   
 
 Disintegration was carried out for three filmstrips using deoinized water as the 
disintegration medium. The time it took for the film to visually break apart were 82, 101 and 115 
seconds. The mean disintegration time was 99.3 ± 16.6 seconds or 1.7 ± 0.3 minutes. A 
disintegration time of lower than 5 minutes was considered satisfactory for this formulation.  
  
In vitro dissolution test   
 
 A seriallydiluted cockroach protein standard is shown in Figure 6. Dissolution time was 
measured for three filmstrips over a period of 45 minutes and the absorbance values were 
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correlated with the constructed standard curve. The release profiles of the strips are shown in 
Figure 7. Total protein release was achieved within 20 minutes. The expectation for an 
immediate release formulation is 80% released within 45 minutes, and in this formulation, 80% 





 Ten strips were randomly selected and their Bla g 2 contents were assayed by ELISA. 
The acceptance value (AV) was calculated using the method set out in the current United States 
Pharmacopeia and equation (1).  
 
AV = | M - X | + ks 
 
The target Bla g 2 content per dosage unit was 25 g/filmstrip, which was set as the label claim. 
RSD was 5.3%, which conforms to the acceptance criteria of less than or equal to 6.0%. The 
maximum allowed acceptance value for each individual preparation was no more than ± 15.0%. 
Based on these values, the tested strips were determined as having acceptable uniformity in 








 Recent studies have highlighted cockroach allergy as an important cause of inner-city 
asthma. In a survey of over 400 children with asthma in the United States, Rosenstrich et 
al19found that having high levels of the cockroach allergen Bla g 2 in the bedroom is correlated 
with asthma morbidity if the children living there also had sensitivity to the allergen. But at the 
same time, the presence of cockroach allergen in the indoor environment is a major risk factor 
for developing sensitization. Bla g 2 is an especially potent allergen due to its increased number 
of disulfide bridges and the zinc cation, both features serve to strength the tertiary structure of 
the allergen and preserve its stability in the environment. Therefore sensitization to Bla g 2 can 
occur even with relatively low amount of exposure20. Cockroaches are ubiquitous, this makes 
prevention by reducing exposure difficult or even impractical to achieve. In one study, the 
reduction of mites and cockroach allergens on the bedroom floor was found to correlate with 
fewer symptom days and less hospital visits due to asthma21. Such abatement interventions can 
become cost-effective in the long run, but the substantial time and resources commitment that is 
required may not always sustain this maintenance duration. Because of this, allergen 
immunotherapy has become the major treatment scheme in that it offers the best hope for a long-
term reduction in hypersensitivity and improved quality of life. 
 Allergen immunotherapy is most often carried out using allergen extracts, at least 30 
million doses are given each year in the US alone22. These are usually given as subcutaneous 
injections, which have serious risks associated with them especially for people with extreme 
sensitivities. Cockroach allergen extracts, along with many others, are nonstandardized allergen 
extracts, but they constitute the majority of products available in the US23. They are labeled 
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either with the weight to volume dilutions of a stock extract, or with protein nitrogen units 
(PNU), both measurements have little relationship with the potency of the allergen, therefore the 
exact dosage used in each immunotherapy is difficult to assess25.  
 The safest approach to immunotherapy is to use extracts and formulations for which the 
allergen potency has been ascertained. Sublingual immunotherapy (SLIT) has rapidly gained 
popularity, since it is a noninvasive and efficacious treatment of common food and respiratory 
allergies24. In this study, our SLIT thin film formulation were formulated as immediate release 
dosage forms. Theycontain known amounts of Bla g 2 allergen; and its potency and stability 
have both been evaluated to ensure theymaintain the critical allergen characteristics over 
time.These films provide an alternative to the current subcutaneous injection in improving 
patient compliance, ease of self-administration, and better bioavailability. 
 The commercial allergen source material that we obtained from Greer contains suitably 
high concentrations of allergen. We optimized the solubilization protocol to ensure consistent 
levels of protein extraction and therefore high Bla g 2 doses in the films. Methocel® E 15 was 
chosen to confer mucoadhesive properties to the films.Visual examination showed that the 
fabricated filmstrips were smooth, lightly transparent with good flexibility, across the entire dose 
range. Physicochemical characterizations performed on the filmstrips show that they are uniform 
in weight and thickness, bear stress well, and can maintain physical integrity during bending and 
pulling. 
 Dosage uniformity has been an ongoing challenge with nonstandardized allergens such as 
the cockroach allergens. With most commercial products having label claims in irrelevant units, 
it carries great risk in immunotherapy when the potency of the formulation cannot be accurately 
determined. We have established a standardized protocol for the extraction of cockroach soluble 
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proteins, as well as for the film casting process. The sublingual films we have developed here 
have been carefully characterized here for their uniformity so that we have full confidence that 
we can achieve the label claim of 25 μg/strip when the research proceeds to manufacturing and 
subsequent clinical trials. 
 Preliminary stability studies conducted for a period of 1 week for the soluble protein 
extract and 9 weeks for the filmstrip prototypes showed no appreciable degradation in allergen 
content. This finding is significant because if the Bla g 2 protein is stable in solution, 
manufacturing of these strips can be done in a much less constrained timeline with no adverse 
effects to the end product. cGMP compliant stability studies are in progress to assess the stability 
of the filmstrips for up to one year, which is the anticipated length of the clinical trial.
 Cockroach allergy is important in the pathogenesis of asthma in the Unites States. In this 
study, we have successfully developed a SLIT thin film formulation using fast dissolving oral 
thin films to treat patients with hypersensitivity to cockroach. The films exhibit good mechanical 
strength, consistent potency and adequate stability. While only the cockroach allergen was 
studied in this report, the SLIT methodology has enormous potential to change the face of 





Table 1. Systematic Nomenclature and Functional Properties of Cockroach Allergens4 
 
Blattella germanica 
Allergen M.W.* Function/homology Accession number Reference 
Bla g 1 ̴ 25-90 
Midgut microvilli protein 
homolog 
  




Bla g 1.0102 25-37 L47595 [57] 
Bla g 1.02 56 
 
AF072220 [58] 
Bla g 2** 36 Unusual aspartic protease U28863 [8; 42; 70] 
Bla g 4 21 Lipocalin U40767 [43] 
Bla g 5 23 Glutathione S-Transferase U92412 [44] 
Bla g 6 17 Troponin C 
  




Bla g 6.0201 
 
DQ279093 [47] 
Bla g 6.0301 
 
DQ279094 [47] 
Bla g 7 33 Tropomyosin AF260897 [49] 
Bla g 8 
 
Myosin light chain DQ389157 [47] 
Periplaneta americana 
Allergen M.W.* Function/homology Accession number Reference 
Per a 1 25-45 
Midgut microvilli protein 
homolog 
  
Per a 1.0101 26 AF072222 [59] 
Per a 1.0102 26 U78970 [60] 
Per a 1.0103 45 U69957 [93] 
Per a 1.0104 31 U69261 [60] 
Per a 1.02 51 U69260 [60] 
Per a 2 36 Unusual aspartic protease AY792947 FT Chew [42] 
Per a 3 46-79 Arylphorin/hemocyanin 
  
Per a 3.01 79 
 
L40818 [45] 
Per a 3.0201 75 L40820 [45] 
Per a 3.0202 56 L40819 [45] 
Per a 3.0203 46 L40821 [45] 
Per a 6 17 Troponin C AY792950 FT Chew [47] 
Per a 7 33 
Tropomyosin 
  
Per a 7.0101 
 
Y14854 [89] 
Per a 7.0102 AF106961 [24] 
Per a 9 Arginine kinase 
  
Per a 9.0101 40 
 
AY563004 [53] 
* Molecular weight calculated from sequence. 



























Hydroxypropyl methylcellulose, sodium caboxymethylcellulose, 
polyethylene oxide, hydroxypropyl cellulose, polyvinylpyrrolidone, 















Table 3. Various types of synthetic polymers and their properties14 
 
Polymer Water solubility pH 
Moisture (% 









Soluble in cold 
water 






6-8 10 90,000-700,000 
 
Polyvinyl alcohol 
Readily soluble 5-8 5 20,000-200,000 
 
Polyethylene oxide 
Readily soluble 8-10 <1 Variable 
 
Kollicoat 



















Table 4. Various types of natural polymers and their properties14 
 
Polymer Water solubility pH 








Slowly soluble, forming 
viscous solution 
7.2 15 - 
 
Pectin 
Soluble in water 6-7.2 10 30,000-100,000 
 
Gelatin 
Swell in water and soften 3.8-6.0 10 15,000-250,000 
 
Maltodextrine 














Table 5. Optimized compositions of the sublingual immunotherapy  
thin film developed in this study 
 
Components Formulation (%w/v) 
Defatted cockroach extract 0 – 40 
Methocel E15 LV Preimium* 50 
Deionized water 49.8 – 9.8 
Glycerin 0.15 
Chocolate flavoring 0.5 















Figure 1. Ribbon representation of the overall fold of Bla g 2. The disulfide bridges and 
polysaccharides are shown in ball-and-stick representation and their location is marked. The 









Figure 2. Structure-based sequence alignment comparing Bla g 2 with porcine pepsin (PEP), 
bovine chymosin (CMS), human renin (RNE), and yeast proteinase A (pA). White letters on the 
pink background indicate residues that are conserved in all five enzymes; pink and orange letters 
are used for residues identical in two or more proteins; green and blue letters denote similar 









   
  Figure 3. Metal-binding site in Bla g 2. A metal ion and the  
  coordinating residues in Bla g 2. The zinc ion is shown as  









































  Figure 5. Typical Stress-Strain curve of a sublingual immunotherapy 
  thin-filmstrip containing 40% aqueous cockroach protein extract (red).   













  Figure 6. Serially diluted standard curve of cockroach aqueous protein   
  extract. Standard concentrations range from 15 ng/mL to 1.5 μg/mL (n=3).  
  UV/Visible spectroscopy was taken at 300nm. Slope of regression    
  represents μg of total protein per film strip.  
  








































 Figure 7. In vitro dissolution profile of sublingual immunotherapy filmstrips (n=6). 
 Samplings times were 5, 10, 15, 20, 25, 30 and 45 minutes. The samples were analyzed 
 on the UV/Vis spectroscopy at 300nm. The results were quantitated against the standard 
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